Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase I Study of DYRK1A Inhibitor FRTX-02

Fresh Tracks Therapeutics, Inc. announced that it has initiated the multiple ascending dose portion of the ongoing Phase I clinical trial in Canada evaluating FRTX-02, the company’s lead drug candidate, in healthy adult subjects.